Digest Network Come funziona
Network
/
Società
Im
Non verificato

Immunome, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

74 comunicati stampa

Guarda tutti i comunicati
30/10/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
26/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
06/10/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
30/09/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
08/09/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
02/09/2026
Web e Social Network
Fiere
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
06/08/2026
Mercato azionario
Finanza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
20/07/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
08/07/2026
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0